Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Faculty of Public Health has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Peter Horby

Professor Peter Horby is honoured for both his longstanding contribution to improving the treatment and control of epidemic infections and his more recent contribution to improving the treatment of COVID-19 through the RECOVERY trial.

In a letter to Prof. Horby, the FPH said he has gained international prominence, which reflects a career of experience and insight in epidemic response.

‘Your relentless focus on health inequities and your commitment to collaboration on public health research, whether at a local or global level, have resulted in an outstanding career and achievements.’

Peter Horby has led clinical and epidemiological research on a wide range of emerging and epidemic infections for almost two decades, including SARS, avian influenza (bird flu), Ebola, Lassa fever, monkeypox, and plague.

During the very earliest days of COVID-19, he worked with colleagues in China to characterise the illness and test new treatments. He co-leads the RECOVERY trial, the largest randomised controlled trial of COVID-19 treatments in the world. The RECOVERY trial changed global treatment practices for COVID-19 three times in 100 days, has delivered results on nine treatments to date, and continues to test treatments in the UK and internationally.

When so many people have done so much in the last two years, I feel incredibly privileged to have been given this prestigious award. There are many lessons from the pandemic, but one that stands out for me is the absolutely central and essential role of public health specialists in protecting health and society. I hope that 2020 will be a watershed, marking a step change in the level of investment and recognition of the public health profession, not just in the UK but globally. Peter Horby

The full story is available on the University of Oxford website

Similar stories

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

The GRAM Project has moved

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.

The RECOVERY Trial - two years on

One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.